Facing regulatory affairs interview questions for freshers is often the first real test for anyone entering pharmaceutical regulatory affairs: unlike other pharma roles, the interviewer expects even a junior candidate to understand the logic of the registration dossier, the European authorisation procedures and the language of ICH guidelines. The good news is that the questions recur with surprising regularity. In this article you will find the questions most frequently asked of junior regulatory affairs candidates, with concrete guidance on how to frame your answers and the mistakes to avoid.
How to Prepare for Regulatory Affairs Interview Questions
An entry-level regulatory affairs interview assesses three things: understanding of the basic regulatory framework, the ability to reason in a structured way, and attention to documentary detail. Nobody expects a fresh graduate to have filed a marketing authorisation application, but everyone expects them to know what a CTD is and the difference between a centralised and a national procedure.
Before the interview, work on three fronts:
- Research the company: products, markets where it registers (EU only? FDA too?), recent announcements on new approvals. The "why us?" questions are won here.
- Review the primary sources: the EMA pages on authorisation procedures, the CTD structure under ICH M4, the Variations Regulation. Citing the right source is worth more than a memorised definition.
- Prepare personal examples: thesis work, internships, project work where you managed documentation, deadlines or formal requirements. Method counts as much as content.
Questions on Regulatory Knowledge: CTD and ICH
"What is the CTD and how is it structured?" The absolute classic. Expected answer: the Common Technical Document, defined by the ICH M4 guideline, is the harmonised format of the registration dossier, organised into five modules. Module 1 contains regional administrative information (the only region-specific module), Module 2 the summaries (Quality Overall Summary, Nonclinical and Clinical Overviews), Module 3 quality (the CMC part), Module 4 the nonclinical study reports and Module 5 the clinical study reports. Bonus point: knowing that the eCTD is the electronic submission format of the same content, not a different dossier.
"Which ICH guidelines do you know?" You do not need the full list: better a few, correctly placed. For example ICH Q8-Q10 for pharmaceutical development, risk management and the quality system, ICH M4 for the dossier format, ICH E6 for GCP. Showing that the Q, S, E and M series cover quality, safety, efficacy and multidisciplinary topics respectively is already a solid answer for a fresher.
Preparing for an interview or taking your first steps in regulatory? Every week The Pragmatic GMP, GuideGxP's free newsletter, turns regulations and regulatory news into practical takeaways: constant revision that makes a difference in front of a recruiter too. Subscribe, it's free.
Questions on European Registration Procedures
"What are the procedures for obtaining a marketing authorisation in Europe?" Here the interviewer wants to hear the four routes and their selection criteria:
| Procedure | Legal basis | Key feature |
|---|---|---|
| Centralised (CP) | Reg. (EC) 726/2004 | A single MA valid throughout the EU/EEA; CHMP evaluation of up to 210 active days, then the Commission decision |
| Mutual Recognition (MRP) | Dir. 2001/83/EC | Extends an existing national MA to other Member States |
| Decentralised (DCP) | Dir. 2001/83/EC | Simultaneous application in several Member States with no pre-existing MA |
| National | Dir. 2001/83/EC | MA valid in a single Member State |
A detail that sets a prepared candidate apart: in the centralised procedure the CHMP scientific evaluation takes up to 210 active days (clock-stops for answering questions do not count), after which the European Commission adopts the binding decision. The EMA does not "grant" the MA: the EMA evaluates, the Commission authorises.
Questions on Post-Approval Variations
"What is the difference between Type IA, IB and II variations?" The reference is Regulation (EC) 1234/2008. The answer to give: Type IA variations are minor changes with minimal or no impact on quality, safety or efficacy, notified under a "do and tell" logic (implement first, then notify); Type IB is the default category for minor variations that fall under neither IA nor II and require notification before implementation; Type II variations are major changes with a potentially significant impact and require prior approval. To impress, you can also mention line extensions and the possibility of grouping and worksharing.
"A production department tells you about a change of excipient supplier: what do you do?" An increasingly common scenario question. The winning answer is the method: I assess the regulatory impact of the change, check its classification in the variations classification guideline, verify in which countries the product is registered, and coordinate the implementation timing with QA and production relative to the approval. A fresher who answers with a process, not a memorised classification, demonstrates maturity.
Behavioural and Soft-Skill Questions
Alongside the technical part, expect questions on accuracy and deadline management, because regulatory affairs lives on non-negotiable regulatory deadlines:
- "Tell me about a time you managed conflicting deadlines." Use the STAR method (Situation, Task, Action, Result) and pick an example involving documents or formal requirements.
- "How do you keep up to date with regulatory news?" Cite primary sources: EMA, ICH, European Commission, FDA websites; possibly industry newsletters. Never answer "I google it".
- "How would you handle a disagreement with an R&D colleague over dossier content?" Show balance: data in hand, reference to the applicable guideline, structured escalation if necessary.
- "Why regulatory affairs and not QA or pharmacovigilance?" Prepare an authentic answer showing you know the real differences between the roles.
GuideGxP Recommendation
The most effective way to prepare is not memorising answers but understanding the logic of the regulatory lifecycle: how an MA application is born, which procedures exist, how the authorisation is maintained over time through variations. Whoever masters this thread can also answer the questions they did not prepare. Build a personal map: for each lifecycle phase, note the reference regulation, the competent authority and the documents involved, and review it the day before the interview.
For structured study, the guide Regulatory Affairs (RA) — Operational guide to marketing authorisation, variations and the regulatory lifecycle of the medicinal product covers exactly the path interview questions are built on: from the MA to variations, with an operational toolkit included.